Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.

Abstract

We performed a retrospective analysis of 101 impotent patients using intracavernous self-injections as primary therapy for vasculogenic impotence. A total of 70 patients used an average of 5.58 micrograms prostaglandin E1 (95% confidence interval 4.83 to 6.34 micrograms) as a single agent, and 31 injected 0.40 ml. (95% confidence interval 0.342 to 0.457 ml.) of a combination of papaverine (12 mg./ml.), phentolamine (1 mg./ml.) and prostaglandin E1 (9 micrograms/ml.). We describe the procedure to establish the dosage for home use and discuss the implications of the low dosages relative to previous reports.

• Authors: B von Heyden, C F Donatucci, N Kaula, T F Lue
• Journal: The Journal of urology (J Urol) Vol. 149 Issue 5 Pt 2 Pg. 1288-90 (May 1993) ISSN: 0022-5347 [Print] United States
• PMID: 8479018 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Papaverine
• Alprostadil
• Phentolamine

Topics

• Adult
• Aged
• Aged, 80 and over
• Alprostadil (administration & dosage, therapeutic use)
• Arteries (drug effects, physiopathology)
• Drug Therapy, Combination
• Erectile Dysfunction (drug therapy, physiopathology)
• Humans
• Injections
• Male
• Middle Aged
• Papaverine (administration & dosage, therapeutic use)
• Penile Erection (drug effects)
• Penis (blood supply)
• Phentolamine (administration & dosage, therapeutic use)
• Retrospective Studies
• Self Administration